BiotechTube

Ofatumumab + Disease modifying treatment (DMT)

ApprovedActive
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Relapsing-Remitting Multiple Sclerosis

Conditions

Relapsing-Remitting Multiple Sclerosis

Trial Timeline

Mar 2, 2022 → Mar 1, 2027

NCT ID
NCT05090371

About Ofatumumab + Disease modifying treatment (DMT)

Ofatumumab + Disease modifying treatment (DMT) is a approved stage product being developed by Novartis for Relapsing-Remitting Multiple Sclerosis. The current trial status is active. This product is registered under clinical trial identifier NCT05090371. Target conditions include Relapsing-Remitting Multiple Sclerosis.

What happened to similar drugs?

6 of 20 similar drugs in Relapsing-Remitting Multiple Sclerosis were approved

Approved (6) Terminated (6) Active (8)
🔄CT-P53 + US-Ocrevus + EU-OcrevusCelltrionPhase 3
❌DaclizumabAbbViePhase 3
❌BIIB019 (Daclizumab)AbbViePhase 3
🔄BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process PlaceboAbbViePhase 3
🔄Rebif® + Avonex®MerckPhase 3
✅Rebif® + Rebif®MerckApproved
✅Interferon beta-1a (Rebif)MerckApproved

Hype Score Breakdown

Clinical
20
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05090371ApprovedActive

Competing Products

20 competing products in Relapsing-Remitting Multiple Sclerosis

See all competitors
ProductCompanyStageHype Score
CT-P53 + US-Ocrevus + EU-OcrevusCelltrionPhase 3
47
LY2127399 + PlaceboEli LillyPhase 2
35
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
35
DaclizumabAbbViePhase 3
32
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
35
BIIB019 (Daclizumab) + trivalent seasonal influenza vaccineAbbViePhase 2
35
BIIB019 (Daclizumab)AbbViePhase 3
32
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process PlaceboAbbViePhase 3
40
Rebif (Interferon beta-1a)MerckPre-clinical
26
Interferon beta-1aMerckPre-clinical
26
Rebif® + Avonex®MerckPhase 3
40
Rebif® + Rebif®MerckApproved
43
VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) aloneMerckPhase 2
35
Placebo + IFN beta-1a + MethylprednisoloneMerckPhase 2
27
Interferon beta-1a (Rebif)MerckApproved
43
Evobrutinib + Avonex® + Avonex® matched Placebo + Evobrutinib matched PlaceboMerckPhase 3
32
Evobrutinib + Avonex® + Avonex® matched Placebo + Evobrutinib matched PlaceboMerckPhase 3
32
Interferon beta 1aMerckPre-clinical
26
Cladribine 10 mg oral tabletMerckApproved
39
Evobrutinib + Evobrutinib + Evobrutinib + Placebo + TecfideraMerckPhase 2
27